Podcasts about cite

Ben Maller talks about Matt Ryan saying he has no interest in playing for the Jets, how many votes of confidence the Jets will give Zach Wilson, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

Like pork? May want to set down your BBQ sandwich before listening to this episode. Let's talk about a rare diagnosis and a great differential for brain masses. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake. 191. BBQ and Brain masses. September 25th, 2023. Accessed [date].

Debate da Super Manhã: Debater o atual cenário da educação, de forma a estimular professores, gestores e demais profissionais da área, com propostas e práticas inclusivas através da tecnologia. Esse é objetivo do 19º Congresso Internacional de Tecnologia na Educação, promovido pelo Sistema Fecomércio/Sesc/Senac Pernambuco, com apoio do Sebrae-PE e do Sistema Jornal do Commercio de Comunicação. O evento tem início nesta quarta-feira (20), nas unidades do Senac do Recife, Caruaru, no Agreste do Estado, em Petrolina, no Sertão Pernambucano, e também na modalidade online. No debate desta terça-feira (19), o comunicador Tony Araujo conversa com os nossos convidados para saber detalhes desse encontro e os avanços tecnológicos na educação. Participam a gerente regional de Processos Educacionais do Senac Pernambuco, Guiomar Albuquerque, a gerente de Desenvolvimento Educacional do Senac Pernambuco, Betânia Paiva, e o coordenador de Avaliação Institucional e Presidente da Comissão Própria de Avaliação (CPA) do Senac Pernambuco, Luiz Costa.

Ben Maller discusses whether or not the criticism of Joe Burrow is warranted, the Jets Sauce Gardner wanting to matchup with top receivers, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

Enjoy going to chiropractors to get your back and neck cracked? Listen to this episode first. Let's talk about a scary, uncommon cause of stroke in young people. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Husain, Iltifat. 190. Cranial Artery dissection and Boba tea. September 18th, 2023. Accessed [date].

Ben Maller talks about Shannon Sharpe saying that Tyreek Hill is scarier than Jerry Rice was, Micah Parsons saying the Cowboys are the best defense in the NFL, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

We promise this isn't clickbait. Hospital administrators take note. We're covering what's important in sepsis care. Take a guess what we won't be covering.... It begins with an L and ends in -actate. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake. 189. Sepsis: burn the stopwatches. September 11th, 2023. Accessed [date].

Ben Maller talks about the level of concern for JuJu Smith-Schuster's knee, Desmond Ridder NOT being named captain for the Falcons, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

This episode focuses on new statutes effective from July 1, 2023, aiming to prevent local building and fire safety officials in Florida from imposing unwarranted requirements after issuing a permit. The post New Rules: Florida Officials Must Cite Code appeared first on TheLienZone Podcast.

Ben Maller talks about Bill Belichick giving a lecture about "overspending" in the NFL being bad for business, why the Cardinals are dragging their feet on naming a starting QB, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

You spent wayyyyy too much time learning G6PD in med school. Don't remember that? Yeah, we don't either. But it's okay- time to cover a much more important hematology subject: hemophilia. How to manage bleeding, what to look out for, and how to easily nail it on the boards. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Husain, Iltifat. 188. Hemophilia: if paper cuts could kill. August 28th, 2023. Accessed [date].

Ben Maller talks about reports that Stefon Diggs is looking to get traded from the Bills, Daniel Jones adding 10 lbs of muscle this offseason and if that matters, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.

Go online to PeerView.com/DBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Peerview “Clinical Consults” based on an immune thrombocytopenia (ITP) symposium at the 2023 ASCO Annual Meeting, experts will focus on preparing learners for the emergence of innovative, BTK inhibitor-based strategies with therapeutic applications in ITP. Throughout, the experts will use conversational, case-centered discussions to explore the persistent challenges in ITP management; the mechanistic rationale and evidence for the use of reversible BTK inhibitors; and the application of new evidence that can be used to update standard ITP protocols, particularly for patients relapsing after prior treatment. Watch this recording to see if you are prepared to implement the new rules for management of ITP! Upon completion of this activity, participants should be better able to: Describe the unmet needs and current clinical burden of ITP management, including lack of durable remissions, the challenges of multiple relapses, and symptoms such as fatigue and anxiety over bleeding; Cite the mechanistic rationale, efficacy, and safety evidence supporting the use of BTK inhibitors in patients with previously treated ITP; Integrate newer therapeutics, including BTK inhibitor-based options, into the management of adults and adolescents with persistent and chronic ITP; and Address practical aspects related to the use of innovative therapeutics in ITP, including management of unique dosing and safety considerations; attention to patient quality of life; and provision of education to patients requiring therapy for relapsed disease.

Go online to PeerView.com/UTY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care. Upon completion of this activity, participants should be better able to: Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance; Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions; Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors; and Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies.

First: Yesterday's charges from Georgia prosecutors against Donald Trump and 18 others trace 161 criminal acts starting before Election Day 2020, citing forgery, intimidation, fraud, perjury, hacking and more.  Plus: Trump's 18 co-defendants in the election heist feature two movie poster names: Mark Meadows, his former chief of staff, and Rudy Giuliani, the former mayor who built his brand on locking up the mob.  And: This fourth criminal indictment of the former president will test Donald Trump's theory that another set of criminal charges will clinch the Republican nomination. To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Ben Maller talks about Justin Herbert getting ranked ahead of Jalen Hurts on The Athletic's rankings of young players, Marcus Allen implying the RB market is poisoned with collusion, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

In this episode Jamie Lewsadder and Dan Ramirez chat about opening of schools strategies and tips.

In the world of law, often known for its conservatism, Ramtin Taheri is revolutionizing the approach. Alongside co-founder Brian Potts, he's established a pioneering marketing agency connecting brands with social media influencers focused on lawyers and law students. Ramtin's agency breaks the mold by leveraging influencers specializing in legal content, bridging the gap between the legal field and modern digital trends. Their curated influencer group offers unique insights into effective strategies for marketing to lawyers. This journey has been an exploration of innovation, distilling legal complexities into concise social media posts and crafting narratives that resonate with legal professionals. Ramtin's agency embodies a shift in redefining how legal practitioners interact with the digital landscape, breathing new life into marketing and the legal community's connection with contemporary dynamics. As law embraces the digital era, Ramtin's agency underscores innovation, collaboration, and progress.

Ben Maller talks about the chances that we see Matt Ryan back in the NFL, the optimism surrounding Justin Fields in training camp, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

Skunks, bats, foxes, dogs, and even raccoons. Friendly Disney animals? Not anymore. Let's talk about rabies- when to vaccinate, when not to, and good board-relevant info that will help you save a patient's wallet (and life too). Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Wosiski-Kuhn, Marlena. 187. Rabies: don't mess with skunks. August 6th, 2023. https://www.emboardbombs.com/podcasts/186-is-charcoal-ever-the-right-answer. Accessed [date]

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.

Go online to PeerView.com/YJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New insight into the biology of myelofibrosis (MF) led to the validation of effective JAK inhibitor–based treatment platforms, setting the stage for subsequent therapeutic advances in this difficult-to-treat myeloproliferative neoplasm. The emergence of newer JAK inhibitor options has fueled additional research on newer mechanisms of action that may soon play a role in conjunction with JAK-based platforms as part of sequential or combination therapy. In this activity, based on a recent live event, expert panelists provide guidance on leveraging these developments when planning care for patients with a variety of comorbid conditions, prognostic features, or treatment experiences. Join the experts now and take your patient care to the next level! Upon completion of this activity, participants should be better able to: Summarize characteristics of myelofibrosis (MF) that are relevant for therapy selection, prognosis, and the use of modern risk assessment models; Cite current evidence on the use of JAK inhibitor platforms and emerging targeted agents in MF management, including as frontline or sequential treatment, in pre-HCT strategies, or in treatment-refractory disease; Integrate modern targeted options into the personalized upfront and sequential management of patients with MF; and Manage safety considerations associated with the use of targeted therapy platforms in MF.

Show notes: Follow Dan on LinkedIn at linkedin.com/in/cotterdan Follow Pat on LinkedIn at https://www.linkedin.com/in/donald-patrick-eckler-610290824/   Predictions Sure To Go Wrong: Van Buren: affirm De'Aquino: affirm 401 North Wabash: affirm Illinois appellate can be found at: https://www.illinoiscourts.gov/courts/appellate-court/oral-argument-audio/

Special counsel Jack Smith filed a request for a protective order in the election interference case, citing a Trump post. It comes as calls grow for cameras in the courtroom of Trump's trials. Plus, some of Lizzo's former dancers filed a lawsuit accusing the singer of sexual harassment and creating a hostile work environment. Glenn Thrush, Katie Benner, Glenn Kirschner, Jon Allen, Reed Galen, Krystie Lee Yandoli and Jon Meacham join.

Ben Maller talks about the idea that Aaron Rodgers won't be able to maintain elite play for 17 games at age 39, why there's no timetable for Kyler Murray's return, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

We're covering a unique overdose you might have seen before: bupropion. Also, we're covering some weird pearls for toxicology. Let's get to it in this short, action-packed episode. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake. 186. Is charcoal EVER the right answer?. July 31st, 2023. https://www.emboardbombs.com/podcasts/186-is-charcoal-ever-the-right-answer. Accessed [date]

Doamne, ajută-ne să manifestăm compasiune față de semenii noștri! Doar atunci vom trăi cu adevărat o viață de slujire autentică. Citește acest devoțional și multe alte meditații biblice pe https://devotionale.ro #devotionale #devotionaleaudio

Sometimes biblical authors drew in material from outside the Bible in order to strengthen their points for their audience.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3279340/advertisement

Sometimes biblical authors drew in material from outside the Bible in order to strengthen their points for their audience.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3279343/advertisement

Sometimes biblical authors drew in material from outside the Bible in order to strengthen their points for their audience.

Go online to PeerView.com/TVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid change is coming to the management of myelodysplastic syndromes (MDS), fueled by new science that will expand the therapeutic possibilities for managing different patient populations and impact the management team. But are you ready to be a team player and help revolutionize MDS care? Find out by viewing this PeerView “Clinical Consults” activity based on a symposium held during the 2023 ASCO Annual Meeting. Watch as an expert panel provides insights on the use of innovative therapies for the first-line management of MDS anemia, the treatment of ESA-refractory patients, and management of patients presenting with high-risk disease. Throughout, they will also provide practical insights for effective delivery of care, including patient education, appropriate dosing, and adverse event management. Don't miss this opportunity to see how your team can take command of care when managing your patients with MDS! Upon completion of this activity, participants should be better able to: Discuss molecular and pathologic features, risk factors, and clinical signs that can inform a timely team-based diagnostic and prognostic assessment of MDS; Cite clinical evidence supporting the use of innovative therapeutics with unique mechanisms of action for the management of patients with low-risk or high-risk MDS; Develop risk-adapted team management of protocols for patients with MDS, including for the first-line management of anemia, in the ESA-failing setting, or for patients presenting with higher-risk genomic subtypes; and Recommend team-based strategies to manage therapy delivery considerations in the MDS setting, including selection of appropriate dosing, response monitoring, and management of therapy-related adverse events

Go online to PeerView.com/YEK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors (BTKi) have transformed the management of mantle cell lymphoma (MCL) and supplanted the serial use of chemoimmunotherapy (CIT) following progression on standard upfront regimens. Ongoing investigations have recently suggested that BTKi-based regimens, including in combination with CIT or CD20 antibodies, may be effective treatment options in the first-line setting. What does this mean in light of new science that has confirmed a role of non-covalent BTKi and immunotherapy as active sequential options in MCL? In this MasterClass & Case Forum activity, based on a symposium recorded during the 2023 ICML conference in Lugano, a panel of experts uses a blended lecture and case-based approach to provide learners with guidance on the differences between covalent BTKi options that can inform treatment selection and how the migration of BTKi to frontline care may impact subsequent treatment decisions with other BTKi strategies, CAR-T, and bispecific antibodies. View this activity now and adapt your practice to reflect the changing times in MCL! Upon completion of this activity, participants should be better able to: Cite the mechanistic, selectivity, and relevant safety profiles of first- and second-generation BTKi options with applications in the MCL setting; Summarize the efficacy evidence supporting the use of BTKi and other innovative strategies across the spectrum of MCL, including newly diagnosed and R/R disease; Select optimal upfront and sequential treatment with novel agent classes, including BTKi, for the management of treatment-naïve and R/R MCL; and Develop protocols to address practical aspects of MCL care when using novel therapeutic strategies, including monitoring, patient/caregiver education, adherence, and AE management

Ben Maller talks about the timeline for Andy Reid to coach the Chiefs, how long it will take the Packers to get a read on Jordan Love, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

If you could start a pro-wrestler team, it would be Toxic Megacolon, obvi. The real question is what's the finishing move? Let's chat Inflammatory bowel disease, Crohn's and UC- their presentation, dealing with flares, and the scary complications. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Wosiski-Kuhn, Marlena. 185. Crohn's and Ulcerative Colitis: Angry Intestines. July 24th, 2023. https://www.emboardbombs.com/podcasts/185-crohns-disease-angry-intestines. Accessed [date]

In this episode Jamie and guest host Dan Ramirez catch up with Jerry Jones and Steve Monahan to go over their recommended steps for disaster recovery, best practices, and any changes since their last chat on the topic. Resources: https://bit.ly/k12drp

Ben Maller talks about Dak Prescott saying he will not have 10 interceptions this season, Le'Veon Bell apologizing to Steelers fans, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

It's already July again? Hello new interns! Hopefully you don't have the worst luck ever and are starting in the Pediatric ED… but let's be honest, we're all scared of neonates. Let's talk Neonatal Fever: tiny humans, BIG infections. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Husain, Iltifat. Ep 184. Neonatal Fever: tiny humans, big infections. July 17th, 2023. https://www.emboardbombs.com/podcasts/184-neonatal-fever-tiny-humans-big-infections. Accessed [date]

Ben Maller talks about Chiefs super-fan "ChiefsAholic" being arrested by the FBI, Jim Irsay's thoughts on playing rookie QB Anthony Richardson, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

As they say in the business, video killed the radio star. This week is our grand opening of our Video podcast. You can now see our smiling faces on Youtube, TikTok, and other social media outlets as we cover a classic pediatric pathology- Epiglottitis! Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Husain, Iltifat. 183. Epiglottitis: video killed the radio star. https://www.emboardbombs.com/podcasts/183-epiglottitis-video-killed-the-radio-star. July 9th, 2023. Accessed [date]

Ben Maller dissects the recent comments Mike Vick said about Andy Reid being the GOAT NFL coach over Bill Belichick. Ben also gives some insight on why the NFL is blaming the Chiefs and Eagles players for slipping at the Super Bowl. Plus, Ben talks about Marvin Harrison Jr.'s draft hype for next year and we have another edition of Cite the Byte!See omnystudio.com/listener for privacy information.

We're giving you a preview of our Rapid Bombs Podcast this week. Check out our video-format on Youtube as well! Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake. Episode 182. Hypotensive, but sweet: a deadly combo. July 3rd, 2023. Accessed [date]

Ben Maller talks about Lionel Messi getting a better deal from MLS team Inter Miami than any player has in the NFL, an apparent bidding war over J.J Watt as a sportscaster, Cite the Bite, and much more!See omny.fm/listener for privacy information.

Need water on that burn brah? Yes actually. Just don't use hydrogen peroxide. Let's stop the transfers of these easy minor burns. Keep it simple and let's talk some key management pearls for the test and practice. Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake. Episode 180. Minor Burn Management: Sick Burn Bro!. https://caper-grape-a35s.squarespace.com/config/pages/6220e223e727543f1b11dca5. June 19th, 2023. Accessed [date]

Ben Maller talks about Saquon Barkley threatening to sit out the entire 2023 season and if the Giants are being unreasonable in their contract stance, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

Call Goose and Maverick. We're diving into the Danger Zone to cover RPAs. These sneaky infections can really cause serious morbidity and mortality. Don't miss this on the exam! Want to experience the greatest in board studying? Check out our interactive question bank podcast- the FIRST of its kind here: emrapidbombs.supercast.com. Cite this podcast as: Briggs, Blake; Hussain, Iltifat. Episode 179. Retropharyngeal abscess and Top Gun. https://www.emboardbombs.com/podcasts/179-retropharyngeal-abscess-and-top-gun. June 12th, 2023. Accessed [date]

Ben Maller talks about the Angels Shohei Ohtani getting compared to Michael Jordan and why he isn't buying that, reports that the A's Vegas stadium is a 50/50 proposition, Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

In this week's Failure Friday segment, we hear from a Boise entrepreneur with the goal of bringing chickens to city dwellers. Alas, in the end the business is forced to flee the coop. Side Hustle School features a new episode EVERY DAY, featuring detailed case studies of people who earn extra money without quitting their job. This year, the show includes free guided lessons and listener Q&A several days each week. Show notes: SideHustleSchool.com Email: team@sidehustleschool.com Be on the show: SideHustleSchool.com/questions Connect on Twitter: @chrisguillebeau Connect on Instagram: @193countries Visit Chris's main site: ChrisGuillebeau.com If you're enjoying the show, please pass it along! It's free and has been published every single day since January 1, 2017. We're also very grateful for your five-star ratings—it shows that people are listening and looking forward to new episodes.